7 results
At this time, iontophoretic administration of S(+)-ketamine is a already in use as a treatment of peripheral neuropathic pain in several pain clinics In the Netherlands (including the pain clinic at the Medical Center in Alkmaar). Although this…
PRIMARY OBJECTIVESParts 1 & 2* To assess safety and tolerability of the combination of GLPG2451 and GLPG2222, with and without GLPG2737 in adult subjects with CF* To characterize the PK of GLPG2451 and GLPG2222, with and without GLPG2737 (…
PRIMARY OBJECTIVES- To investigate the PK profile of GLPG2451 administered as two doses of a capsule formulation in healthy subjects.- To assess the safety and tolerability of GLPG2451 administered as two doses of a capsule formulation in healthy…
Evaluation of the feasibility of a trial on the efficacy of oral esketamine for the treatment of depression and/or demoralization in patients with advanced cancer who receive palliative care.
The proposed study aims to examine the antidepressant efficacy of oral S-ketamine augmentation in patients with TRD treated with regular antidepressants in a double-blind randomised controlled trial. Secondary questions involve the effects of oral S…
Objective: Primary objective: To determine pharmacokinetic profiles of an esketamine oral thin film with 50 or 100 mg esketamine; Secondary objective: (1) To determine the pharmacodynamic profile of an esketamine oral thin film containing 50 or 100…
The primary objective is to investigate whether pharmacological conditioning with S(+)-ketamine compared to pharmacological conditioning with placebo medication reduces pain sensitivity in patients with FMS.